Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment

Core Insights - Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company is conducting a Phase 3 clinical study for avexitide, which targets adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery [1][4] Clinical Trial Details - The Phase 3 Lucidity clinical study of avexitide has randomized and dosed its final subject, with a total of 78 participants enrolled [2] - The study is designed as a 16-week multicenter, randomized, double-blind, placebo-controlled trial, with the possibility of extending for an additional 32 weeks if participants complete the initial phase [2] - Topline data from the trial is expected to be released in the third quarter of 2026, with avexitide anticipated to be available for sale in 2027 if approved [2] Analyst Insights - H.C. Wainwright analyst Andrew Fein has raised the price target for Amylyx Pharmaceuticals from $28 to $34, maintaining a Buy rating on the shares [2] - The firm has increased its probability of success estimate for the avexitide program, indicating heightened confidence in its potential [3] Company Focus - Amylyx Pharmaceuticals specializes in the discovery and development of treatments for endocrine and neurodegenerative diseases, with a portfolio that includes AMX0318 (avexitide), AMX0035, and AMX0114 at various stages of clinical trials [4]